Monday, August 20, 2018

Investor Ideas #Potcasts #Cannabis News and #Stocks on the Move: TSX: $ACB.TO, CSE: $MTEC.C, CSE: $LIB.C


Investor Ideas #Potcasts #Cannabis News and #Stocks on the Move: TSX: $ACB.TO, CSE: $MTEC.C, CSE: $LIB.C




Delta, Kelowna, BC –August 20, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its “potcast’ site, www.potcasts.ca  release today’s edition of its series, Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:


Today’s podcast overview/transcript:

Good morning and welcome to another Investorideas.com potcast – looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today we will be looking at announcements from Aurora Cannabis Inc. trading on the TSX as ACB and the OTCQB as ACBFF, Cannvas MedTech Inc. trading on the CSE as MTEC and Liberty Leaf Holdings Ltd. trading on the CSE as LIB and the OTCQB as LIBFF.

Aurora Cannabis Inc. today announced that, in connection with the spin-out of its subsidiary Australis Capital Inc., Aurora has set Friday August 24, 2018 as the record date for the distribution of Australis units.

Canadian shareholders as at the record date will be eligible to receive the Distribution. Non-resident shareholders will be entitled to receive a cash payment net of any applicable withholding taxes following a sale of their respective units in the open market by an independent custodian following the Distribution. Consequently, Aurora anticipates the completion of the Distribution to shareholders and the public listing of Australis on the CSE to be completed in September 2018.

Cannvas MedTech Inc., a leading business technology company in the cannabis space, and CanvasRx, a wholly owned subsidiary of Aurora Cannabis Inc. operating 29 clinics across Canada, announced the signing of a letter of intent, to negotiate, in good faith, a patient aggregation agreement after an exploratory period of up to six months during which Cannvas and CanvasRx agree to mutually create data models through the Cannvas.me platform suited for CanvasRx's B2B and B2C businesses.

With strong partnerships, a network of clinics, and access to, and information on hundreds of strains of medical cannabis from the top Licensed Producers in Canada, CanvasRx has developed a powerhouse of education and information for the cannabis industry. People use CanvasRx to learn about medical cannabis, find knowledgeable doctors, select strains and track their outcomes with Patient Reporting tools developed by physicians.

During the exploratory period, Cannvas will develop specific parameters within its existing Cannvas Data framework to collect data and analytics from CanvasRx and their strategic partnerships, and provide CanvasRx with access to the Cannvas.me dataset. CanvasRx will benefit from using Cannvas.me proprietary databases and algorithms to gain insights to their existing and future membership base. The two companies will work together to enhance user experiences across each respective online platform and explore ways to improve the overall education of visitors in a non-biased and independent method, including positioning the Cannvas.me educational platform within the CanvasRx chain of medical cannabis clinics.

Liberty Leaf Holdings Ltd. announced the completion of its first CBD research trial on pain medication for dogs.
Liberty Leaf has a Collaborative Agreement with ESEV Research Development, a leading Israeli-American research and development company, for them to conduct research into the efficacy of CBD-containing products for treating specific medical conditions in pets.  The project is being managed and overseen by Pharmaseed, ESEV's partner in Israel.
This is the first study of several to be conducted under the Collaborative Agreement.  The study included large mixed-breed dogs, which received a proprietary CBD-infused oil formulation or placebo in the active phase of study. Oral CBD-infused oil provides the most effective means of delivery of CBD to dogs. 
The focus of this first study was on treating dogs with chronic osteoarthritic pain. Osteoarthritis (OA) is one of the most common diseases in dogs, characterized by pain, stiffness, lethargy and decreased mobility, which leads to reduction in their quality of life. 

CBD offers a potential solution for both owner and pet.  In fact, dogs should be able to take advantage of the pain management capabilities of CBD even more so than humans since dogs have a more extensive endocannabinoid system with which CBD can interact.  This interaction helps to reduce pain and other symptoms linked to the endocannabinoid system.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com  website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   


Subscribe to the new cannabis podcast series:


To hear more Investorideas.com podcasts visit: http://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the Stock Guru daily podcast on Support and Resistance Trading.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: http://www.investorideas.com/About/Private_Policy.asp


Follow us on Social Media





Contact Investorideas.com
800-665-0411




Do you trade or invest in Marijuana / Hemp Stocks?  Check out our stock directory of publicly traded  CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks
Join our Group on Linkedin  and talk about - Marijuana / Hemp Stocks - News and Trends in Green Investing


No comments:

Post a Comment